IRD vs RGNX
IRD: Opus Genetics is a clinical-stage gene therapy company developing a portfolio of durable, one-time treatments for rare inherited retinal diseases. RGNX: A clinical-stage gene therapy developer leveraging its proprietary AAV platform to create potentially curative, one-time treatments for serious genetic diseases.
Side-by-side fundamentals
| Metric | IRD | RGNX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $4.46 | $8.09 | |
| Market cap | $371M | $534M | |
| Net margin FY2025, SEC XBRL | -349.3% | -113.8% | RGNX higher |
| Operating margin FY2025, SEC XBRL | -271.9% | -94.6% | RGNX higher |
| ROE FY2025, SEC XBRL | -323.1% | -188.7% | RGNX higher |
| ROA FY2025, SEC XBRL | -98.7% | -42.8% | RGNX higher |
| Debt / equity as of 2026-09-02 | 0.07 | 2.53 | IRD lower |
| Revenue growth (YoY) as of 2026-09-02 | -12.2% | +12.0% | RGNX higher |
| Revenue CAGR (3y) SEC XBRL | -29.1% | +14.8% | RGNX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.78 | 1.88 | |
| 1-year return as of 2026-10-08 close | +117.6% | -33.8% | IRD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.